Jefferies upgraded Sabra Health Care to Buy from Hold with a price target of $15, up from $11. The analyst sees “significant upside embedded” in the senior housing segment and says the company’s triple-net portfolio has been “significantly de-risked.” As such, Sabra’s current valuation presents a compelling entry point, the analyst tells investors in a research note. The firm expects senior housing occupancy and cash net operating income margin to increase materially over the next two years, driven by macro tailwinds and micro adjustments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SBRA:
- The Market Shifts for Healthcare REITs
- Sabra Health Care upgraded to Neutral at BofA on senior housing recovery
- Sabra Health Care upgraded to Neutral from Underperform at BofA
- Sabra Health Care reports Q2 FFO 33c, consensus 34c
- Sabra Healthcare Reit (SBRA) Q2 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com